Company Snapshot
- Ticker
- MRK
- Name
- MRK
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 250449480000.000000
- Volume
- 16,432,639
- Avg Volume (3M)
- 12,810,212
MRK
MRK
Last update recent
100.26
-0.04
(-0.04%)
Market Cap
250449480000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 64235000000.000000
- EPS
- 7.59
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 3.24%
- Net Income
- 19034000000.000000
- Net Margin
- 29.63%
- Payout Ratio
- 42.6%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 13.16
- Forward P/E
- None
- P/S
- 3.90
- P/B
- 4.83
- Beta
- None
- Debt / Equity
- 0.80
- Current Ratio
- 1.66
- Return on Equity
- 0.37%
- Return on Assets
- 0.15%
Technicals & Returns
- Distance vs 200 DMA
- 19.21%
- 200 DMA
- 84.11
- Distance vs 50 DMA
- 9.37%
- 50 DMA
- 91.67
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identif Read more
- Name
- MRK
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Robert M. Davis J.D.
- Employees
- 70,000
- IPO Date
- 1978-01-13
- Phone
- 908 740 4000
- Address
- None
- Website
- https://www.merck.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-09-16 • $0.77
Latest News
Curated headlines from premium sources.
MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH
Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.
Merck & Co., Inc. $MRK Shares Bought by Corient Private Wealth LLC
Corient Private Wealth LLC increased its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 85.6% in the undefined quarter, according to the company in its …
Cullen Capital Management LLC Grows Holdings in Merck & Co., Inc. $MRK
Cullen Capital Management LLC grew its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 1.8% in the second quarter, according to its most recent disclosur…
Caxton Associates LLP Increases Stake in Merck & Co., Inc. $MRK
Caxton Associates LLP grew its holdings in Merck and Co., Inc. (NYSE: MRK) by 23.3% during the undefined quarter, according to its most recent Form 13F filing …
Rep. Julie Johnson Sells Off Shares of Merck & Co., Inc. (NYSE:MRK)
Representative Julie Johnson (D-Texas) recently sold shares of Merck and Co., Inc. (NYSE: MRK). In a filing disclosed on December 11th, the Representative disc…
Caldwell Trust Co Purchases Shares of 48,103 Merck & Co., Inc. $MRK
Caldwell Trust Co acquired a new stake in Merck and Co., Inc. (NYSE: MRK) during the second quarter, according to its most recent disclosure with the Securitie…